cepharanthine has been researched along with Alveolitis, Fibrosing in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, G; Dou, G; Gan, H; Gu, R; Han, P; Li, J; Liu, T; Meng, Z; Wang, F; Wu, Z; Zhu, X | 1 |
| Chen, G; Dou, G; Gan, H; Gu, R; Han, P; Li, J; Liang, D; Liu, H; Liu, M; Liu, S; Liu, T; Meng, Z; Wu, Z; Zhou, H; Zhu, X | 1 |
2 other study(ies) available for cepharanthine and Alveolitis, Fibrosing
| Article | Year |
|---|---|
Bioavailability Enhancement of Cepharanthine via Pulmonary Administration in Rats and Its Therapeutic Potential for Pulmonary Fibrosis Associated with COVID-19 Infection.
Topics: Animals; Benzylisoquinolines; Biological Availability; Bleomycin; Chromatography, Liquid; COVID-19; COVID-19 Drug Treatment; Humans; Lung; Pulmonary Fibrosis; Rats; Tandem Mass Spectrometry; Transforming Growth Factor beta1 | 2022 |
Cepharanthine Ameliorates Pulmonary Fibrosis by Inhibiting the NF-κB/NLRP3 Pathway, Fibroblast-to-Myofibroblast Transition and Inflammation.
Topics: Animals; Bleomycin; Collagen; COVID-19; Fibroblasts; Inflammation; Lung; Myofibroblasts; NF-kappa B; NLR Family, Pyrin Domain-Containing 3 Protein; Pulmonary Fibrosis; Rats; Transforming Growth Factor beta1 | 2023 |